The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma. The U.S. Food and Drug Administration (FDA) has ...

b Performed 3 months later at the outpatient clinic. c For conversion to mg/dl divide by 0.0555. d For conversion to mg/dl divide by 88.4. a Performed at presentation. b Performed 3 months later ...

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025. The FDA granted priority review to a supplemental new ...

A pheochromocytoma is a type of tumor found in the adrenal glands or certain nerve cells. These tumors are very rare but can cause dramatic symptoms because they tend to secrete large amounts of ...